Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 27, 2010

View Archived Issues

Briakinumab is superior to methotrexate and etanercept in treating psoriasis

Long-term data disclosed on alemtuzumab for treatment of relapsing-remitting MS

GM-CSF adjuvant enhances efficacy of AIDS vaccine in rhesus macaques

BMS-690514 shows potential to treat non-small cell lung cancer

Combination of BG-12 with IFN-beta 1a or glatiramer acetate is safe in healthy subjects

Pfizer gains exclusive global rights to commercialize several of Biocon's insulin products

Vertex Pharma begins phase IIIb telaprevir trial in hepatitis C

Phase II Androxal trial begins in men with type 2 diabetes and low testosterone

AstraZeneca presents novel glucocorticoid receptor ligands

New inhibitors of dual specificity protein kinase TTK presented

Continuation recommended of phase III LibiGel safety trial

Boehringer Ingelheim and MacroGenics to codevelop antibody-based therapeutics

Celtic Therapeutics and Resolvyx Pharma form ophthalmology alliance

Preliminary data reported from phase II orBec trial in prevention of GVHD

Essentialis and FDA reach agreement on SPA for diazoxide choline trial

New inhibitors of HCV NS5A presented

Roche patents new glucocorticoid receptor antagonists

ViaDerm delivery system meets endpoints in phase I osteoporosis trial

Verona Pharma treats first patient in trial of VRP-700 in chronic cough

MDS to change company name to Nordion

Inviragen begins phase I trial for DENVax dengue virus vaccine

MolMed begins enrollment in phase II trial of NGR-hTNF in soft tissue sarcomas

Daiichi Sankyo receives Japanese approval for new formulations of Cravit

Interim safety results reported from toxicology study of CEQ-508

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...